16 results on '"Chabot, Donald"'
Search Results
2. Protection of rhesus macaques against inhalational anthrax with a Bacillus anthracis capsule conjugate vaccine
- Author
-
Chabot, Donald J., Ribot, Wilson J., Joyce, Joseph, Cook, James, Hepler, Robert, Nahas, Debbie, Chua, Jennifer, and Friedlander, Arthur M.
- Published
- 2016
- Full Text
- View/download PDF
3. Engineering an Fc-Fusion of a Capsule Degrading Enzyme for the Treatment of Anthrax.
- Author
-
Matharoo, Khushie, Chua, Jennifer, Park, Junyoung R., Ingavale, Susham, Jelacic, Tanya M., Jurkouich, Kayla M., Compton, Jaimee R., Meinig, J. Matthew, Chabot, Donald, Friedlander, Arthur M., and Legler, Patricia M.
- Published
- 2022
- Full Text
- View/download PDF
4. The capsule of Bacillus anthracis protects it from the bactericidal activity of human defensins and other cationic antimicrobial peptides.
- Author
-
O'Brien, David K., Ribot, Wilson J., Chabot, Donald J., Scorpio, Angelo, Tobery, Steven A., Jelacic, Tanya M., Wu, Zhibin, and Friedlander, Arthur M.
- Subjects
DEFENSINS ,ANTIMICROBIAL peptides ,BACILLUS anthracis ,POLYMYXIN B ,MELITTIN - Abstract
During infection, Bacillus anthracis bacilli encounter potent antimicrobial peptides (AMPs) such as defensins. We examined the role that B. anthracis capsule plays in protecting bacilli from defensins and other cationic AMPs by comparing their effects on a fully virulent encapsulated wild type (WT) strain and an isogenic capsule-deficient capA mutant strain. We identified several human defensins and non-human AMPs that were capable of killing B. anthracis. The human alpha defensins 1–6 (HNP-1-4, HD-5-6), the human beta defensins 1–4 (HBD-1-4), and the non-human AMPs, protegrin, gramicidin D, polymyxin B, nisin, and melittin were all capable of killing both encapsulated WT and non-encapsulated capA mutant B. anthracis. However, non-encapsulated capA mutant bacilli were significantly more susceptible than encapsulated WT bacilli to killing by nearly all of the AMPs tested. We demonstrated that purified capsule bound HBD-2, HBD-3, and HNP-1 in an electrophoretic mobility shift assay. Furthermore, we determined that the capsule layer enveloping WT bacilli bound and trapped HBD-3, substantially reducing the amount reaching the cell wall. To assess whether released capsule might also play a protective role, we pre-incubated HBD-2, HBD-3, or HNP-1 with purified capsule before their addition to non-encapsulated capA mutant bacilli. We found that free capsule completely rescued the capA mutant bacilli from killing by HBD-2 and -3 while killing by HNP-1 was reduced to the level observed with WT bacilli. Together, these results suggest an immune evasion mechanism by which the capsule, both that enveloping the bacilli and released fragments, contributes to virulence by binding to and inhibiting the antimicrobial activity of cationic AMPs. Author summary: Bacillus anthracis causes anthrax after spores infect the skin, respiratory tract, or gastrointestinal tract. Antimicrobial peptides (AMPs), such as defensins, are a first line of host defense that B. anthracis encounters in all of these tissues. B. anthracis bacteria are covered by a capsule that protects them from being engulfed and destroyed by phagocytic immune cells. In this study, we found that the capsule also provides protection from AMPs. An encapsulated B. anthracis strain is resistant to killing by multiple AMPs from humans and other species compared to an otherwise identical strain that is not encapsulated. By binding defensins the capsule surrounding the bacilli reduces the amount that gets to the bacterial cell wall where it can do damage. B. anthracis bacteria release large fragments of capsule in the host during infection and during growth in culture. We found that purified released capsule can bind defensins and reduce killing of non-encapsulated B. anthracis. Thus, both capsule covering the bacteria and capsule shed by the bacteria can contribute to the pathogenicity of B. anthracis by providing protection from AMPs. Our study reveals a new mechanism by which B. anthracis capsule contributes to virulence. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Capsule depolymerase overexpression reduces Bacillus anthracis virulence
- Author
-
Scorpio, Angelo, Chabot, Donald J., Day, William A., Hoover, Timothy A., and Friedlander, Arthur M.
- Subjects
Bacillus anthracis -- Physiological aspects ,Bacillus anthracis -- Genetic aspects ,Bacillus anthracis -- Research ,Bacterial infections -- Control ,Bacterial infections -- Genetic aspects ,Bacterial infections -- Research ,Peptidyl transferases -- Physiological aspects ,Peptidyl transferases -- Genetic aspects ,Peptidyl transferases -- Research ,Virulence (Microbiology) -- Genetic aspects ,Virulence (Microbiology) -- Research ,Biological sciences - Abstract
Capsule depolymerase (CapD) is a [gamma]-glutamyl transpeptidase and a product of the Bacillus anthracis capsule biosynthesis operon. In this study, we examined the effect of modulating capD expression on B. anthracis capsule phenotype, interaction with phagocytic cells and virulence in guinea pigs. Transcriptional fusions of capD were made to the genes encoding heat-shock protein 60 (hsp60) and elongation factor Tu (EFTu), and to capA, a B. anthracis capsule biosynthesis gene. Translation signals were altered to improve expression of capD, including replacing the putative ribosome-binding site with a consensus sequence and the TTG start codon with ATG. CapD was not detected by immunoblotting in lysates from wild-type B. anthracis Ames but was detected in strains engineered with a consensus ribosome-binding site for capD. Strains overexpressing capD at amounts detected by immunoblotting were found to have less surface-associated capsule and released primarily lower-molecular-mass capsule into culture supernatants. Overexpression of capD increased susceptibility to neutrophil phagocytic killing and adherence to macrophages and resulted in reduced fitness in a guinea pig model of infection. These data suggest that B. anthracis may have evolved weak capD expression resulting in optimized capsule-mediated virulence. DOI 10.1099/mic.0.035857-0
- Published
- 2010
6. Treatment of experimental anthrax with pegylated circularly permuted capsule depolymerase.
- Author
-
Legler, Patricia M., Little, Stephen F., Senft, Jeffrey, Schokman, Rowena, Carra, John H., Compton, Jaimee R., Chabot, Donald, Tobery, Steven, Fetterer, David P., Siegel, Justin B., Baker, David, and Friedlander, Arthur M.
- Published
- 2021
- Full Text
- View/download PDF
7. Anthrax capsule vaccine protects against experimental infection
- Author
-
Chabot, Donald J., Scorpio, Angelo, Tobery, Steven A., Little, Stephen F., Norris, Sarah L., and Friedlander, Arthur M.
- Published
- 2004
- Full Text
- View/download PDF
8. Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.
- Author
-
Vietri, Nicholas J, Tobery, Steven A, Chabot, Donald J, Ingavale, Susham, Somerville, Brandon C, Miller, Jeremy A, Schellhase, Chris W, Twenhafel, Nancy A, Fetterer, David P, Cote, Christopher K, Klimko, Christopher P, Boyer, Anne E, Woolfitt, Adrian R, Barr, John R, Wright, Mary E, and Friedlander, Arthur M
- Subjects
CLINDAMYCIN ,ANTHRAX ,CIPROFLOXACIN ,TOXINS ,BACILLUS anthracis ,ANTIBIOTICS ,ANTHRAX prevention ,BIOLOGICAL models ,RESEARCH ,COMBINATION drug therapy ,ANIMAL experimentation ,RESEARCH methodology ,BACILLUS (Bacteria) ,BACTERIAL antigens ,RESPIRATORY infections ,PROGNOSIS ,MEDICAL cooperation ,EVALUATION research ,TREATMENT effectiveness ,PRIMATES ,COMPARATIVE studies ,RESEARCH funding ,BACTERIAL toxins ,PHARMACODYNAMICS - Abstract
Background: Inhalational anthrax is rare and clinical experience limited. Expert guidelines recommend treatment with combination antibiotics including protein synthesis-inhibitors to decrease toxin production and increase survival, although evidence is lacking.Methods: Rhesus macaques exposed to an aerosol of Bacillus anthracis spores were treated with ciprofloxacin, clindamycin, or ciprofloxacin + clindamycin after becoming bacteremic. Circulating anthrax lethal factor and protective antigen were quantitated pretreatment and 1.5 and 12 hours after beginning antibiotics.Results: In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin. These differences were not statistically significant. There were no significant differences between groups in lethal factor or protective antigen levels from pretreatment to 12 hours after starting antibiotics. Animals that died after clindamycin had a greater incidence of meningitis compared to those given ciprofloxacin or ciprofloxacin + clindamycin, but numbers of animals were very low and no definitive conclusion could be reached.Conclusion: Treatment of inhalational anthrax with clindamycin was as effective as ciprofloxacin in the nonhuman primate. Addition of clindamycin to ciprofloxacin did not enhance reduction of circulating toxin levels. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Anthrax toxin-induced rupture of artificial lipid bilayer membranes.
- Author
-
Nablo, Brian J., Panchal, Rekha G., Bavari, Sina, Nguyen, Tam L., Gussio, Rick, Ribot, Wil, Friedlander, Art, Chabot, Donald, Reiner, Joseph E., Robertson, Joseph W. F., Balijepalli, Arvind, Halverson, Kelly M., and Kasianowicz, John J.
- Subjects
BILAYER lipid membranes ,ORGAN rupture ,ANTHRAX toxin ,ENDOSOMES ,CHROMOSOMAL translocation ,CYTOPLASM ,BACILLUS anthracis - Abstract
We demonstrate experimentally that anthrax toxin complexes rupture artificial lipid bilayer membranes when isolated from the blood of infected animals. When the solution pH is temporally acidified to mimic that process in endosomes, recombinant anthrax toxin forms an irreversibly bound complex, which also destabilizes membranes. The results suggest an alternative mechanism for the translocation of anthrax toxin into the cytoplasm. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Strict Conservation of the Retroviral Nucleocapsid Protein Zinc Finger Is Strongly Influenced by Its Role in Viral Infection Processes: Characterization of HIV-1 Particles Containing Mutant Nucleocapsid Zinc-Coordinating Sequences
- Author
-
Gorelick, Robert J., Gagliardi, Tracy D., Bosche, William J., Wiltrout, Theresa A., Coren, Lori V., Chabot, Donald J., Lifson, Jeffrey D., Henderson, Louis E., and Arthur, Larry O.
- Published
- 1999
- Full Text
- View/download PDF
11. Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys
- Author
-
Chabot, Donald J., Joyce, Joseph, Caulfield, Michael, Cook, James, Hepler, Robert, Wang, Su, Vietri, Nicholas J., Ruthel, Gordon, Shoop, Wesley, Pitt, Louise, Leffel, Elizabeth, Ribot, Wilson, and Friedlander, Arthur M.
- Subjects
- *
ANTHRAX vaccines , *LABORATORY rabbits , *LABORATORY monkeys , *ENZYME-linked immunosorbent assay , *BACILLUS anthracis , *BACTERIAL capsules , *MEMBRANE proteins , *LABORATORY mice - Abstract
Abstract: Bacillus anthracis, the causative agent of anthrax, is recognized as one of the most serious bioterrorism threats. The current human vaccines are based on the protective antigen component of the anthrax toxins. Concern about possible vaccine resistant strains and reliance on a single antigen has prompted the search for additional immunogens. Bacterial capsules, as surface-expressed virulence factors, are well-established components of several licensed vaccines. In a previous study we showed that an anthrax vaccine consisting of the B. anthracis poly-γ-d-glutamic acid capsule covalently conjugated to the outer membrane protein complex of Neisseria meningitidis serotype B protected mice against parenteral B. anthracis challenge. Here we tested this vaccine in rabbits and monkeys against an aerosol spore challenge. The vaccine induced anti-capsule antibody responses in both species, measured by ELISA and a macrophage opsono-adherence assay. While rabbits were not protected against a high aerosol challenge dose, significant protection was observed in monkeys receiving the capsule conjugate vaccine. The results confirm that the capsule is a protective immunogen against anthrax, being the first non-toxin antigen shown to be efficacious in monkeys and suggest that addition of capsule may broaden and enhance the protection afforded by protective antigen-based vaccines. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
12. Immunogenicity and Protective Efficacy of Bacillus anthracis PoIy-γ-D-glutamic Acid Capsule Covalently Coupled to a Protein Carrier Using a Novel Triazine-based Conjugation Strategy.
- Author
-
Joyce, Joseph, Cook, James, Chabot, Donald, Hepler, Robert, Shoop, Wesley, Qiuwei Xu, Stambaugh, Thomas, Aste-Amezaga, Miguel, Su Wang, Indrawati, Lani, Bruner, Mark, Friedlander, Arthur, Keller, Paul, and Caulfield, Michael
- Subjects
- *
IMMUNOGENETICS , *BACILLUS anthracis , *GLUTAMIC acid , *POLYMERS , *DICHROISM , *ACTIVATION (Chemistry) - Abstract
The capsular polypeptide of Bacillus anthracis is composed of a unique polyglutamic acid polymer in which o-glutamate monomers are joined by γ-peptidyl bonds. The capsule is poorly immunogenic, and efforts at exploiting the polymer for vaccine development have focused on increasing its inherent immunogenicity through chemical coupling to immune-stimulating protein carriers. The usual strategy has employed carbodiimide-based condensing reagents for activation of free α-carboxyl groups, despite reports that this chemistry may lead to chain scission. We have purified the high molecular mass capsule to > 95% homogeneity and have demonstrated that the polymer contains > 99% poly-γ-D-glutamic acid. The predominant structure of the polymer as assessed by circular dichroism and multiangle laser light scattering was unordered at near-neutral pH. We investigated the effects of various activation chemistries, and we demonstrated that carbodiimide treatment under aqueous conditions results in significant cleavage of the γ-peptidyl bond, whereas scission is significantly reduced in nonaqueous polar solvents, although undesired side chain modification was still observed. An activation chemistry was developed using the triazine-based reagent 4-(4,6-dimethoxy (1,3,5)triazin-2-yl)-4-methylmorpholinium chloride, which allowed for controlled and reproducible derivatization of a-carbonyls. In a two-pot reaction scheme, activated capsule was derivatized with a sulfhydryl-reactive heterobifunctional moiety and was subsequently coupled to thiolated carrier protein. This conjugate elicited very high capsule-specific immune titers in mice. More importantly, mice immunized with conjugated capsule exhibited good protection against lethal challenge from a virulent B. anthracis strain in two models of infection. We also showed, for the first time, that treatment of capsule with carbodiimide significantly reduced recognition by capsule-specific antisera concurrent with the reagent-induced reduction of polymer mass. The data suggested that for vaccine development, maintenance of the high mass of the polymer may be important. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
13. Poly-γ-Glutamic Acid Encapsulation of Bacillus anthracis Inhibits Human Dendritic Cell Responses.
- Author
-
Jelacic TM, Ribot WJ, Tobery SA, Chabot DJ, and Friedlander AM
- Subjects
- Cytokines metabolism, Humans, Immunity, Innate, Phagocytosis, Polyglutamic Acid immunology, Tumor Necrosis Factor-alpha metabolism, Bacillus anthracis immunology, Bacterial Capsules immunology, Dendritic Cells immunology, Macrophages immunology, Polyglutamic Acid analogs & derivatives
- Abstract
The capsule of Bacillus anthracis is composed of a d isomer poly-γ-glutamic acid polymer, which is especially nonstimulatory to dendritic cells, even more so than similar mixed d, l isomer polymers from nonpathogenic Bacillus species. Capsule is an essential virulence factor for B. anthracis , protecting the bacilli from phagocytosis by innate immune cells. In this study, we demonstrate that encapsulation provides a further pathogenic advantage by shielding more inflammatory Ags on the bacillus surface, thereby reducing dendritic cell responses. We exposed human immature dendritic cells (DCs) to increasing multiplicities of infection (MOIs) of killed B. anthracis bacilli from the fully encapsulated wild-type Ames strain (WT) and an isogenic capsule-deficient strain ( capA mutant). Both strains elicited robust cytokine responses, but IL-23, TNF-α, and IL-10 were significantly reduced in response to the encapsulated WT compared with capA mutant up to an MOI of 15. capA mutant bacilli could induce phenotypic maturation of immature DCs with upregulation of MHC classes I and II, CD83, and CCR7 at an MOI of 3.75, whereas encapsulated WT bacilli still did not induce significant upregulation of MHC classes I and II at an MOI of 15. DCs exposed to capA mutant bacilli (MOI 3.75) exhibited CCR7-dependent chemotaxis that was comparable to that of LPS-stimulated controls, whereas DCs exposed to encapsulated WT bacilli exhibited significantly less chemotaxis. We conclude that capsule shields more inflammatory surface Ags, delaying development of an adaptive immune response by reducing TNF-α, thereby inhibiting DC maturation., (Copyright © 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
14. Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens.
- Author
-
Chua J, Chabot DJ, Putmon-Taylor T, and Friedlander AM
- Subjects
- Animals, Anthrax microbiology, Anthrax prevention & control, Antigens, Bacterial immunology, Fluorescein-5-isothiocyanate metabolism, Fluorescence, Humans, Macrophages immunology, Mice, Primates immunology, Primates microbiology, RAW 264.7 Cells, Anthrax immunology, Anthrax Vaccines immunology, Antibodies, Bacterial immunology, Bacillus anthracis immunology, Bacterial Adhesion, Opsonin Proteins immunology
- Abstract
The opsono-adherence assay is a functional assay that enumerates the attachment of bacterial pathogens to professional phagocytes. Because adherence is requisite to phagocytosis and killing, the assay is an alternative method to opsono-phagocytic killing assays. An advantage of the opsono-adherence assay is the option of using inactivated pathogens and mammalian cell lines, which allows standardization across multiple experiments. The use of an inactivated pathogen in the assay also facilitates work with biosafety level 3 infectious agents and other virulent pathogens. In our work, the opsono-adherence assay was used to assess the functional ability of antibodies, from sera of animals immunized with an anthrax capsule-based vaccine, to induce adherence of fixed Bacillus anthracis to a mouse macrophage cell line, RAW 264.7. Automated fluorescence microscopy was used to capture images of bacilli adhering to macrophages. Increased adherence was correlated with the presence of anti-capsule antibodies in the serum. Non-human primates that exhibited high serum anti-capsule antibody concentrations were protected from anthrax challenge. Thus, the opsono-adherence assay can be used to elucidate the biological functions of antigen specific antibodies in sera, to evaluate the efficacy of vaccine candidates and other therapeutics, and to serve as a possible correlate of immunity.
- Published
- 2020
- Full Text
- View/download PDF
15. Exposure to Bacillus anthracis capsule results in suppression of human monocyte-derived dendritic cells.
- Author
-
Jelacic TM, Chabot DJ, Bozue JA, Tobery SA, West MW, Moody K, Yang D, Oppenheim JJ, and Friedlander AM
- Subjects
- Cells, Cultured, Humans, Interleukin-6 metabolism, Interleukin-8 metabolism, Bacillus anthracis immunology, Bacterial Capsules immunology, Dendritic Cells drug effects, Dendritic Cells immunology, Immune Tolerance
- Abstract
The antiphagocytic capsule of Bacillus anthracis is a major virulence factor. We hypothesized that it may also mediate virulence through inhibition of the host's immune responses. During an infection, the capsule exists attached to the bacterial surface but also free in the host tissues. We sought to examine the impact of free capsule by assessing its effects on human monocytes and immature dendritic cells (iDCs). Human monocytes were differentiated into iDCs by interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) over 7 days in the presence of capsule derived from wild-type encapsulated B. anthracis Ames (WT) or a control preparation from an isogenic B. anthracis Ames strain that produces only 2% of the capsule of the WT (capA mutant). WT capsule consistently induced release of IL-8 and IL-6 while the capA mutant control preparation elicited either no response or only a minimal release of IL-8. iDCs that were differentiated in the presence of WT capsule had increased side scatter (SSC), a measure of cellular complexity, when assessed by flow cytometry. iDCs differentiated in the presence of WT capsule also matured less well in response to subsequent B. anthracis peptidoglycan (Ba PGN) exposure, with reduced upregulation of the chemokine receptor CCR7, reduced CCR7-dependent chemotaxis, and reduced release of certain cytokines. Exposure of naive differentiated control iDCs to WT capsule did not alter cell surface marker expression but did elicit IL-8. These results indicate that free capsule may contribute to the pathogenesis of anthrax by suppressing the responses of immune cells and interfering with the maturation of iDCs., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Published
- 2014
- Full Text
- View/download PDF
16. Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.
- Author
-
Scorpio A, Chabot DJ, Day WA, O'brien DK, Vietri NJ, Itoh Y, Mohamadzadeh M, and Friedlander AM
- Subjects
- Animals, Antigens, Bacterial genetics, Antigens, Bacterial metabolism, Bacillus anthracis drug effects, Bacillus anthracis genetics, Bacillus subtilis drug effects, Bacillus subtilis metabolism, Bacterial Proteins genetics, Bacterial Proteins metabolism, Bacterial Proteins pharmacology, Bacterial Toxins genetics, Bacterial Toxins metabolism, Bacterial Toxins pharmacology, Cells, Cultured, Macrophages cytology, Macrophages drug effects, Macrophages metabolism, Mice, Phagocytosis drug effects, Recombinant Proteins metabolism, Recombinant Proteins pharmacology, gamma-Glutamyl Hydrolase metabolism, gamma-Glutamyltransferase genetics, gamma-Glutamyltransferase pharmacology, Bacillus anthracis metabolism, Bacterial Capsules metabolism, Polyglutamic Acid metabolism, gamma-Glutamyltransferase metabolism
- Abstract
The poly-gamma-d-glutamic acid capsule confers antiphagocytic properties on Bacillus anthracis and is essential for virulence. In this study, we showed that CapD, a gamma-polyglutamic acid depolymerase encoded on the B. anthracis capsule plasmid, degraded purified capsule and removed the capsule from the surface of anthrax bacilli. Treatment with CapD induced macrophage phagocytosis of encapsulated B. anthracis and enabled human neutrophils to kill encapsulated organisms. A second glutamylase, PghP, a gamma-polyglutamic acid hydrolase encoded by Bacillus subtilis bacteriophage PhiNIT1, had minimal activity in degrading B. anthracis capsule, no effect on macrophage phagocytosis, and only minimal enhancement of neutrophil killing. Thus, the levels of both phagocytosis and killing corresponded to the degree of enzyme-mediated capsule degradation. The use of enzymes to degrade the capsule and enable phagocytic killing of B. anthracis offers a new approach to the therapy of anthrax.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.